Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension

Circulation

Volumn 125, Issue 10, 2012, Pages 1266-1275

  Bellien, Jeremy ^a,b   Iacob, Michele ^a,b   Remy Jouet, Isabelle ^b   Lucas, Daniele ^d   Monteil, Christelle ^b   Gutierrez, Laurence ^a   Vendeville, Cathy ^b   Dreano, Yvonne ^d   Mercier, Alain ^c   Thuillez, Christian ^a,b   Joannides, Robinson ^a,b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c UNIVERSITY OF ROUEN   (France)

^d BREST UNIVERSITY HOSPITAL   (France)

Author keywords

Arteries; Endothelium derived factors; Epoxyeicosatrienoic acids; Hypertension

Indexed keywords

ENDOTHELIN 1; EPOXYICOSATRIENOIC ACID; FLUCONAZOLE; N(G) METHYLARGININE; NITRIC OXIDE;

ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FEMALE; HEATING; HUMAN; HYPEREMIA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIAL ARTERY; SHEAR STRESS;

14-ALPHA DEMETHYLASE INHIBITORS; ADULT; EICOSANOIDS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; FLUCONAZOLE; HOT TEMPERATURE; HUMANS; HYPEREMIA; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; OMEGA-N-METHYLARGININE; PULSATILE FLOW; RADIAL ARTERY; REACTIVE OXYGEN SPECIES; SKIN; STRESS, MECHANICAL;

EID: 84858376035     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.070680     Document Type: Article

References (34)

1. Vanhoutte PM, Shimokawa H, Tang EH, Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf). 2009;196:193-222.
2. Bellien J, Joannides R, Richard V, Thuillez C. Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases? Pharmacol Ther. 2011;131:1-17.
3. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002;40:505-510. (Pubitemid 34833167)
4. G-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens. 1992;10:1025-1031.
5. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-1474. (Pubitemid 23133089)
6. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998;97:2222-2229. (Pubitemid 28265383)
7. Cardillo C, Campia U, Kilcoyne CM, Bryant MB, Panza JA. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation. 2002;105:452-456. (Pubitemid 34141701)
8. Taddei S, Versari D, Cipriano A, Ghiadoni L, Galetta F, Franzoni F, Magagna A, Virdis A, Salvetti A. Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients. J Am Coll Cardiol. 2006;48:508-515. (Pubitemid 44093964)
9. Ghiadoni L, Versari D, Magagna A, Kardasz I, Plantinga Y, Giannarelli C, Taddei S, Salvetti A. Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients. J Hypertens. 2007;25:361-366. (Pubitemid 46071933)
10. Gao J, Bellien J, Gomez E, Henry JP, Dautreaux B, Bounoure F, Skiba M, Thuillez C, Richard V. Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in renovascular hypertension. J Hypertens. 2011;29:1128-1135.
11. Bellien J, Iacob M, Gutierrez L, Isabelle M, Lahary A, Thuillez C, Joannides R. Crucial role of NO and endothelium-derived hyperpolarizing factor in human sustained conduit artery flow-mediated dilatation. Hypertension. 2006;48:1088-1094. (Pubitemid 44772712)
12. Bertrand-Thiebault C, Masson C, Siest G, Batt AM, Visvikis-Siest S. Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line. J Cardiovasc Pharmacol. 2007;49:306-315. (Pubitemid 46855125)
13. Goulitquer S, Dréano Y, Berthou F, Corcos L, Lucas D. Determination of epoxyeicosatrienoic acids in human red blood cells and plasma by GC/MS in the NICI mode. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;876:83-88.
14. MacArthur PH, Shiva S, Gladwin MT. Measurement of circulating nitrite and S-nitrosothiols by reductive chemiluminescence. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:93-105. (Pubitemid 46720142)
15. Bruno CM, Neri S, Sciacca C, Caruso L. Plasma endothelin-1 levels in liver cirrhosis. Int J Clin Lab Res. 2000;30:169-172. (Pubitemid 32176910)
16. Lauer T, Heiss C, Preik M, Balzer J, Hafner D, Strauer BE, Kelm M. Reduction of peripheral flow reserve impairs endothelial function in conduit arteries of patients with essential hypertension. J Hypertens. 2005;23:563-569. (Pubitemid 40684715)
17. Joannides R, Haefeli W, Linder L, Richard V, Bakkali ElH, Thuillez C, Lüscher T. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314-1319.
18. Joannidès R, Bakkali ElH, Richard V, Moore N, Thuillez C. Evaluation of the determinants of flow-mediated radial artery vasodilatation in humans. Clin Exper Hypertens. 1997;19:813-826. (Pubitemid 27321706)
19. Rassaf T, Heiss C, Hendgen-Cotta U, Balzer J, Matern S, Kleinbongard P, Lee A, Lauer T, Kelm M. Plasma nitrite reserve and endothelial function in the human forearm circulation. Free Radic Biol Med. 2006;41:295-301. (Pubitemid 43928502)
20. Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P, Balzer J, Zotz RB, Scharf RE, Willers R, Schechter AN, Feelisch M, Kelm M. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med. 2006;40:295-302. (Pubitemid 43069353)
21. Förstermann U, Li H. Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol. 2011;164:213-223.
22. Fichtlscherer S, Dimmeler S, Breuer S, Busse R, Zeiher AM, Fleming I. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation. 2004;109:178-183. (Pubitemid 38114136)
23. Fischer D, Landmesser U, Spiekermann S, Hilfiker-Kleiner D, Hospely M, Müller M, Busse R, Fleming I, Drexler H. Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure. Eur J Heart Fail. 2007;9:770-775. (Pubitemid 47212832)
24. Weintraub NL, Fang X, Kaduce TL, Van Rollins M, Chatterjee P, Spector AA. Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res. 1997;81:258-267. (Pubitemid 27342493)
25. Minuz P, Jiang H, Fava C, Turolo L, Tacconelli S, Ricci M, Patrignani P, Morganti A, Lechi A, McGiff JC. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension. 2008;51:1379-1385. (Pubitemid 351555953)
26. Loch D, Hoey A, Morisseau C, Hammock BO, Brown L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys. 2007;47:87-98.
27. Saito Y, Nakao K, Mukoyama M, Imura H. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med. 1990;322:205. (Pubitemid 20036412)
28. Elijovich F, Laffer CL, Amador E, Gavras H, Bresnahan MR, Schiffrin EL. Regulation of plasma endothelin by salt in salt-sensitive hypertension. Circulation. 2001;103:263-268. (Pubitemid 32095413)
29. Wang GX, Cai SX, Wang PQ, Ouyang KQ, Wang YL, Xu SR. Shearinduced changes in endothelin-1 secretion of microvascular endothelial cells. Microvasc Res. 2002;63:209-217.
30. Spieker LE, Lüscher TF, Noll G. ETA receptors mediate vasoconstriction of large conduit arteries during reduced flow in humans. J Cardiovasc Pharmacol. 2003;42:315-318. (Pubitemid 37071686)
31. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1423-1431.
32. Richard V, Hogie M, Clozel M, Löffler BM, Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation. 1995;91:771-775.
33. Morawietz H, Talanow R, Szibor M, Rueckschloss U, Schubert A, Bartling B, Darmer D, Holtz J. Regulation of the endothelin system by shear stress in human endothelial cells. J Physiol. 2000;525:761-770. (Pubitemid 30426795)
34. Mullen MJ, Kharbanda RK, Cross J, Donald AE, Taylor M, Vallance P, Deanfield JE, MacAllister RJ. Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res. 2001;88:145-151. (Pubitemid 32147301)